Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Jose Muñoz Iglesias"'
Autor:
Mercedes Riveira-Martin, Lara Struelens, Werner Schoonjans, Isaac Sánchez-Díaz, Jose Muñoz Iglesias, Óscar Ferreira Dávila, Francisco Javier Salvador Gómez, Manuel Salgado Fernández, Antonio López Medina
Publikováno v:
EJNMMI Physics, Vol 9, Iss 1, Pp 1-20 (2022)
Abstract Background Since it was first approved in Europe in 2016, the gallium-68 (68Ga) radiopharmaceutical [68Ga]Ga-DOTA-TOC has been widely used for imaging of somatostatin receptor (SSTR) positive tumours using positron emission tomography–comp
Externí odkaz:
https://doaj.org/article/96609cd7263c4c2ca8bd910603476044
Autor:
Ms Mercedes Riveira-Martin, Lara Struelens, Werner Schoonjans, Olivier Van Hoey, Jose Muñoz Iglesias, Sonia Martínez Bernárdez, Francisco Salvador Gómez, Antonio López Medina
Publikováno v:
Physica Medica. 104:S42
Autor:
Mercedes Riveira-Martin, Lara Struelens, José Muñoz Iglesias, Werner Schoonjans, Olga Tabuenca, José Manuel Nogueiras, Francisco Javier Salvador Gómez, Antonio López Medina
Publikováno v:
EJNMMI Physics, Vol 10, Iss 1, Pp 1-25 (2023)
Abstract Background The use of lutetium-177 (177Lu)-based radiopharmaceuticals in peptide receptor nuclear therapy is increasing, but so is the number of nuclear medicine workers exposed to higher levels of radiation. In recent years, [177Lu]Lu-DOTA-
Externí odkaz:
https://doaj.org/article/77d516bee5354e929fd6bdd7e54f3241
Autor:
Rocio Vilchez Simo, Maria Carmen Areses Manrique, María Rosario García Campelo, Cristina Azpitarte Raposeiras, Jose Muñoz Iglesias, Joaquín Martínez, Urbano Anido Herranz, F.J. Afonso, Natalia Fernández Núñez, David Arias Ron, Begoña Campos Balea, Martin Lázaro Quintela, Juan Ruiz Bañobre, Jorge García González, Margarita Amenedo Gancedo, Lucía Santomé Couto, José Luis Fírvida Pérez, Joaquin Casal Rubio, Jesús García Mata, Guillermo Alonso-Jaudenes Curbera, Iria Carou Frieiro
Publikováno v:
Journal of geriatric oncology. 12(3)
Background Nivolumab is an anti PD1 immunotherapy drug approved for advanced Non-Small Cell Lung Cancer (NSCLC) patients who previously received at least one prior line of treatment. Older patients are often not represented in clinical trials and dru
Autor:
Natalia Fernández Núñez, Martin Lázaro Quintela, Iria Carou Frieiro, Joaquin Mosquera Martinez, Margarita Amenedo Gancedo, Joaquin Casal Rubio, Jose Muñoz Iglesias, Alexandra Sabela Cortegoso mosquera, Rocio Vilchez Simo, Urbano Anido Herranz, Jesús García Mata, Lucía Santomé Couto, Begoña Campos Balea, Mª Carmen Areses Manrique, Jorge García González, Mª Rosario García Campelo, Guillermo Alonso-Jaudenes Curbera, José Luis Fírvida Pérez, Cristina Azpitarte Raposeiras, F.J. Afonso
Publikováno v:
Translational Lung Cancer Research. 7:404-415
Background Recently, immunotherapy has changed the standard of treatment in non-small cell lung cancer (NSCLC). Outside clinical trials, data of real life is lacking. This is an observational study that represents the real world experience with nivol